ReviewJournal of clinical medicine2023
Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Attention-Deficit/Hyperactivity Disorder Treatment Patterns and Association With Clinical Outcomes in Adolescents and Young Adults with Co-Occurring Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder: A Retrospective Analysis.Journal of the American Academy of Child and Adolescent Psychiatry · 2026Article
- Retrospectively reported childhood ADHD symptoms and addiction severity in emerging adults with substance use disorders: cross-sectional indirect associations through time perspective.BMC psychiatry · 2026Article
- Substance Use in Adolescents with ADHD and Bipolar Spectrum Disorders: The Transdiagnostic Role of Emotional Dysregulation, Impulsivity and Hypersensitivity Traits.Journal of clinical medicine · 2026Article
- Factors Associated with Reduced Clinical Response in Adult ADHD: The Role of Alcohol and Cannabis Use Disorders and Autism Spectrum Disorder.Journal of clinical medicine · 2026Article
- Requiem for Many Dreams? Comorbid Substance Use and Disruptive Behaviour Disorders in Adolescents.Indian journal of psychological medicine · 2026Article
- Article
- Using a controlled stimulant to treat cocaine use disorder in the setting of attention deficit/hyperactivity disorder: a case study.Frontiers in psychiatry · 2026Article
- Ritual to relief: ethical frontiers in repurposing psychoactive substances.CNS spectrums · 2025Review
- ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives.International journal of molecular sciences · 2025Review
- Holistic Management of Adult ADHD with a History of Addiction: Emphasis on Low-Addiction-Risk Psychopharmacotherapy.Journal of clinical medicine · 2025Review
- Fueling the Cycle: Attachment, Cognition, and Emotion in Substance-Using Incarcerated Young Adults.Clinical neuropsychiatry · 2025Article
- Article
- Review of the psychometric properties and measurement invariance of the Adult Self-Report Scale for ADHD in a sample of employees in Puerto Rico.Frontiers in psychiatry · 2025Article
- Attention Deficit Hyperactivity Disorder: A Risk Factor for Premature Discontinuation of Inpatient Opioid Withdrawal Treatment.Journal of clinical medicine · 2024Article
- Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Training of Awareness in ADHD: Leveraging Metacognition.Journal of psychiatry and brain science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adults with attention deficit/hyperactivity disorder (ADHD) often present psychiatric comorbidities and, in particular, substance use disorder (SUD). ADHD-SUD comorbidity is characterized by greater severity of both disorders, earlier age of onset, higher likelihood of polydrug-abuse and suicidal behaviors, more hospitalizations, and lower treatment adherence. At the present stage, research focused on the pharmacological management of ADHD with comorbid SUD in both adolescents and adults is still lacking. Furthermore, while the short-term effects of stimulants are well studied, less is known about the chronic effects of these drugs on dopamine signaling. Current available evidence is consistent in reporting that high doses of stimulant medications in ADHD-SUD subjects have a mild to moderate efficacy on ADHD symptoms. Some data suggest that pharmacological treatment with stimulants may be beneficial for both ADHD symptoms and comorbid cocaine or amphetamine use. However, in the long run, stimulant medications may have a potential risk for misuse. For the absence of potential misuse, atomoxetine is often recommended for ADHD with comorbid cocaine or amphetamine use disorder. However, its efficacy in reducing addictive behavior is not demonstrated. In subjects with other subtypes of SUD, both atomoxetine and stimulant drugs seem to have scarce impact on addictive behavior, despite the improvement in ADHD symptomatology. In this population, ADHD treatment should be combined with SUD-specific strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.